England Adds PFAS Testing to Annual Population Health Survey
- John Davis
- 946 reads
Urine testing will establish a UK population baseline for PFAS, with initial results expected in 2027. The data may help identify exposure patterns over time.

England’s annual Health Survey will begin measuring PFAS in urine samples, giving researchers a first UK-wide population baseline for these persistent chemicals. The initial results are expected in 2027. For communities concerned about nearby industrial sources, the change could provide a reference point for understanding how local measurements compare with exposure across the wider population.
The UK Health Security Agency (UKHSA) said PFAS will be screened alongside other chemicals, including lead and arsenic, using samples collected through the existing survey. The plan creates a way to track population exposure over time. It does not, however, provide routine individual blood tests or establish what a particular person’s result would mean for their long-term health.
What population monitoring can show
Biomonitoring measures chemicals or their breakdown products in biological samples. In this case, PFAS will be measured in urine. Repeated survey sampling can help researchers describe the range of exposure in the population and look for changes over time. It may also help identify groups whose measured levels differ from the broader pattern, including people with occupational exposure or those living near a source of contamination.
A population baseline is useful because a measurement needs context. Without UK reference data, a result from a particular community is difficult to compare with the wider population using local evidence. A national survey can supply that point of comparison, although it cannot by itself explain how exposure occurred or establish that a measured level caused a health effect.
The distinction matters for people seeking individual answers. UKHSA has said it remains opposed to routine blood testing for PFAS because, in its view, there is not enough evidence to determine what action should follow from a specific result. The new programme is designed to build evidence about population exposure, while questions about individual testing and the health meaning of specific measurements remain unresolved.
Why the baseline is being sought
PFAS, or per- and polyfluoroalkyl substances, are a large group of chemicals used in products that include cookware and school uniforms. Researchers have investigated potential health effects for years. A landmark study in the Mid-Ohio Valley in the United States, begun in the mid-2000s, reported probable links between exposure and thyroid disease, testicular and kidney cancers, and other health consequences.
Concern has also focused on communities near industrial sources, including sites associated with firefighting foam production. In Thornton-Cleveleys, where a PFAS manufacturing plant formerly operated, an independent study published last month found residents’ blood levels of PFOA were elevated compared with baseline levels recorded in the United States. That local finding cannot stand in for a national comparison, which is one reason UK-wide measurements are being sought.
David Megson, an environmental forensics researcher at Manchester Metropolitan University who led the Thornton-Cleveleys analysis, welcomed the new monitoring. He said he had advocated for it for a long time and described it as an important first step toward understanding the PFAS burden in the UK. A national reference, he said, would help communities and individuals who believe they have had high exposure understand what typical exposure looks like in the country.
Megson also cautioned that the results could show the UK has more ground to make up than places that have taken earlier action on PFAS. He said he feared the general population might carry a higher burden than populations in areas such as the United States, while stressing that he hoped the data would prove otherwise. That is a concern, not a result the survey has established.
Health evidence remains unsettled
Stephanie Metzger, a sustainable chemicals policy advisor at the Royal Society of Chemistry, said baseline measurements would help track trends and indicate whether some groups have unusually high levels, potentially linked to work or residence near a PFAS hotspot. Such comparisons could guide further investigation, but measurements alone cannot identify the source of a person’s exposure.
UKHSA director Edward Wynne-Evans said important evidence gaps remain about what different exposure levels mean for an individual’s long-term health. He said the agency’s work includes research, biomonitoring and evidence reviews. In his account of the evidence available so far, the strongest findings relate to possible associations with raised cholesterol and potentially lower birth weight; he said more work is needed to understand those findings and their significance.
That assessment leaves two distinct tasks: measuring exposure and determining what the measurements mean for health. A national survey can strengthen the first. The second depends on further evidence about exposure levels, health outcomes and the circumstances in which people encounter PFAS.
Hélène Duguy, a lawyer at environmental law charity ClientEarth, said clearer exposure data should be accompanied by action to phase out PFAS to prevent future pollution. The monitoring programme will make UK-wide exposure easier to assess, but sampling does not itself remove chemicals from products or prevent releases from industrial sources.
The first results, expected in 2027, will show what the survey can contribute as a reference for population exposure. The practical value will depend on continued measurement and on how researchers use the data to examine differences between groups and changes over time. For affected communities, the new baseline should make comparisons more meaningful; it will not, on its own, settle the health questions or pinpoint the source of exposure.